Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

<h4>Background</h4> <p>Cross-resistance after first-line antiretroviral treatment (ART) failure is expected to impair activity of nucleoside-reverse-transcriptase-inhibitors (NRTIs) in second-line therapy, but evidence for effect on virological outcomes is limited.</p> <h...

Full description

Bibliographic Details
Main Authors:	Paton, N, Kityo, C, Thompson, J, Nankya, I, Bagenda, L, Hoppe, A, Hakim, J, Kambugu, A, van Oosterhout, J, Kinconco, M, Bertagnolio, S, Easterbrook, P, Mugyenyi, P, Walker, A
Format:	Journal article
Published:	Elsevier 2017

Similar Items

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
by: Hakim, J, et al.
Published: (2017)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
by: Hakim, J, et al.
Published: (2017)

Evolution of protease inhibitor resistance in HIV-1-infected patients failing protease inhibitor monotherapy as second-line therapy in low-income countries: an observational analysis within the EARNEST randomised trial
by: Thompson, J, et al.
Published: (2018)

Neurocognitive function at the first-line failure and on the second-line antiretroviral therapy in Africa: Analyses from the EARNEST trial.
by: Kambugu, A, et al.
Published: (2016)

Impact of sub-optimal HIV viral control on activated T-cells: an earnest sub study
by: Arrigoni, FIF, et al.
Published: (2023)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
by: Paton, N, et al.
Published: (2014)

HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa
by: Kityo, C, et al.
Published: (2017)

Archery in earnest /
by: 365963 Matthews, Roy, et al.
Published: (1985)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
by: George W Rutherford, et al.
Published: (2016-01-01)

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
by: Reid, A, et al.
Published: (2008)

Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
by: Anna Maria Geretti, et al.
Published: (2013-01-01)

Time to be in earnest : a fragment of autobiography /
by: James, P. D., author
Published: (1999)

HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors
by: Nicolas Tardiota, et al.
Published: (2024-01-01)

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.
by: Esnouf, R, et al.
Published: (1995)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa
by: Paton, N, et al.
Published: (2014)

HEPT: From an investigation of lithiation of nucleosides towards a rational design of non-nucleoside reverse transcriptase inhibitors of HIV-1
by: Tanaka, H, et al.
Published: (1999)

’Foucault's Ironies and the Important Earnestness of Theory’
by: Mark D. Jordan
Published: (2012-09-01)

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
by: A. V. Kravchenko, et al.
Published: (2018-07-01)

Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study
by: Julien Riou, et al.
Published: (2021-10-01)

Does tenofovir-containing first-line antiretroviral therapy mitigate the impact of pretreatment non-nucleoside reverse transcriptase inhibitor drug resistance?
by: Inzaule, SC, et al.
Published: (2018)

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
by: Ren, J, et al.
Published: (2008)

The long-term outcomes of antiretroviral treatment initiated with mono or dual nucleoside reverse transcriptase inhibitors in HIV-1-infected children: an Asian observational study
by: Orasri Wittawatmongkol, et al.
Published: (2015-07-01)

2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
by: Chan, J, et al.
Published: (2001)

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
by: Murugesan Vanangamudi, et al.
Published: (2023-09-01)

Current scenario on non-nucleoside reverse transcriptase inhibitors (2018-present)
by: Cui Deng, et al.
Published: (2022-12-01)

Lipidic strategy for improving bioavailability of nucleoside HIV reverse transcriptase inhibitor
by: N. S. Shastina, et al.
Published: (2011-04-01)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Valeria Famiglini, et al.
Published: (2016-02-01)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
by: Hopkins, A, et al.
Published: (2004)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
by: Walker, A, et al.
Published: (2012)

Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting
by: Watcharananan Siriorn, et al.
Published: (2007-11-01)

Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2.
by: Milton, J, et al.
Published: (1998)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
by: Peter V. Coveney, et al.
Published: (2012-07-01)

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial
by: Parikh, S, et al.
Published: (2013)

The Lysine 65 Residue in HIV-1 Reverse Transcriptase Function and in Nucleoside Analog Drug Resistance
by: Scott J. Garforth, et al.
Published: (2014-10-01)

Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition.
by: R Brad Jones, et al.
Published: (2008-01-01)

The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors
by: Lívia da Rocha Fernandes, et al.
Published: (2023-11-01)

Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations
by: Anna Stachowicz-Kuśnierz, et al.
Published: (2023-08-01)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance.
by: Meytal Galilee, et al.
Published: (2018-01-01)

Modeling of cytotoxicity on some non- nucleoside reverse transcriptase inhibitors of HIV-1: role of physicochemical parameters
by: B.K. Tiwari, et al.
Published: (2006-02-01)

Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
by: Pelemans, H, et al.
Published: (1998)